文献速递静脉血栓栓塞慢性静脉疾病

急性髂股静脉血栓形成中早期与常规从低分子肝素转换为利伐沙班维持治疗的有效性和安全性:回顾性队列研究

Effectiveness and Safety of Early Versus Routine Switching from Low-Molecular-Weight Heparin to Maintenance Therapy of Rivaroxaban for Acute Iliofemoral Vein Thrombosis: A Retrospective Cohort Study.
PubMed 文献 · Ann Vasc Surg · 2024-05-28

该回顾性队列研究纳入217例急性髂股深静脉血栓患者,比较早期转换(低分子肝素≤7天)与常规转换(>7天)至利伐沙班20 mg每日一次维持治疗的效果与安全性。早期转换组住院时间显著短于常规转换组(7天 vs 14天,P<0.001),两组复发静脉血栓栓塞、大出血、临床相关非大出血及全因死亡率均无统计学差异。

要点

  • 早期转换组住院时间7天,常规转换组14天,差异有统计学意义(P<0.001)。
  • 住院时间与低分子肝素使用时长呈显著正相关(r=0.762,P<0.001)。
  • 两组复发静脉血栓栓塞、大出血、临床相关非大出血及全因死亡率无统计学差异。

核心结论

  • 对于急性髂股深静脉血栓,从低分子肝素直接早期转换为利伐沙班维持治疗是有效且安全的。

研究设计与样本

  • 回顾性队列研究,纳入217例接受初始低分子肝素抗凝后转为利伐沙班维持治疗的急性髂股深静脉血栓患者。

主要发现

  • 早期转换组59例(27.2%),常规转换组158例(72.8%)。
  • 早期转换组住院时间7天 vs 常规转换组14天,P<0.001。
  • 住院时间与低分子肝素使用时长显著正相关(r=0.762,P<0.001)。
  • 复发静脉血栓栓塞发生率早期转换组5.1% vs 常规转换组2.5%,P=0.606。
  • 大出血发生率早期转换组0% vs 常规转换组1.9%,P=0.564;临床相关非大出血1.7% vs 2.5%,P=1.000;全因死亡率6.8% vs 2.5%,P=0.283。

关键数值与推荐

  • 指南推荐初始低分子肝素治疗1周后转换为利伐沙班用于急性髂股深静脉血栓的治疗。
  • 转换策略中利伐沙班初始剂量以及早期转换(不足1周)的有效性和安全性证据尚不充分。
  • 本研究利伐沙班维持治疗剂量为20 mg每日一次。

临床怎么用

  • 对于急性髂股深静脉血栓,可考虑在低分子肝素治疗≤7天后早期转换为利伐沙班20 mg每日一次维持治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The anticoagulation strategy of switching to rivaroxaban after 1 week of initial low-molecular-weight heparin (LMWH) therapy is recommended by a guideline for the treatment of acute iliofemoral deep vein thrombosis (DVT). However, the initial rivaroxaban dose in the switching strategy, as well as the effectiveness and safety of the early switching (less than 1 week) to rivaroxaban, remain inadequately substantiated. We aimed to evaluate the effectiveness and safety of early switching from LMWH to maintenance therapy of rivaroxaban (20 mg once daily) for acute iliofemoral DVT. METHODS: A retrospective cohort study was conducted using data from patients with acute iliofemoral DVT who received initial LMWH anticoagulation followed by rivaroxaban maintenance therapy. The clinical outcomes were compared between early (LMWH course ≤7 days) and routine (LMWH course >7 days) switching strategies within 3 months of initiating anticoagulation. RESULTS: 217 patients were included, 59 (27.2%) receiving early switching and 158 (72.8%) receiving routine switching. Compared with routine switching, patients with early switching had a significantly shorter hospital stay (7 days vs. 14 days, P < 0.001). The length of hospital stay was significantly positively correlated with the duration of LMWH (r = 0.762, P < 0.001). The incidences of recurrent venous thromboembolism (5.1% vs. 2.5%, P = 0.606), major bleeding (0% vs. 1.9%, P = 0.564), clinically relevant nonmajor bleeding (1.7% vs. 2.5%, P = 1.000) and all-cause mortality (6.8% vs. 2.5%, P = 0.283) were not statistically different between the 2 groups. CONCLUSIONS: Direct early switching from LMWH to maintenance therapy of rivaroxaban is effective and safe for acute iliofemoral DVT.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Hou W, Fang D, Yin S, et al. Effectiveness and Safety of Early Versus Routine Switching from Low-Molecular-Weight Heparin to Maintenance Therapy of Rivaroxaban for Acute Iliofemoral Vein Thrombosis: A Retrospective Cohort Study. Ann Vasc Surg. 2024. PMID: 38815910. doi:10.1016/j.avsg.2024.03.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。